---
title: Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated
  AML
date: '2024-05-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38691678/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240502181202&v=2.18.0.post9+e462414
source: Blood
description: Although NPM1-mutated acute myeloid leukemia (AML) carries a generally
  favorable prognosis, many patients still relapse and die. Previous studies identified
  several molecular and clinical features associated with poor outcome, however only
  FLT3-ITD mutation and adverse karyotype are currently used for risk stratification
  due to inconsistent results and uncertainty around how other factors should influence
  treatment, particularly given the strong prognostic impact of post-induction ...
disable_comments: true
---
Although NPM1-mutated acute myeloid leukemia (AML) carries a generally favorable prognosis, many patients still relapse and die. Previous studies identified several molecular and clinical features associated with poor outcome, however only FLT3-ITD mutation and adverse karyotype are currently used for risk stratification due to inconsistent results and uncertainty around how other factors should influence treatment, particularly given the strong prognostic impact of post-induction ...